Should HIV patients be considered a high risk group for the development of prostate cancer?

Annals of the Royal College of Surgeons of England

Volumn 87, Issue 6, 2005, Pages 437-438

  Quatan, Nadine ^a,b   Nair, Sabarinath ^a   Harrowes, Fran ^a   Hay, Phillip ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

HIV; Prostate cancer

Indexed keywords

ANTIANDROGEN; ANTIRETROVIRUS AGENT; BICALUTAMIDE; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LEUPRORELIN; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PROSTATE SPECIFIC ANTIGEN; STAVUDINE; STRONTIUM; TAMOXIFEN; TENOFOVIR; ZIDOVUDINE;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER SCREENING; CASE REPORT; EVIDENCE BASED MEDICINE; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LEUKOCYTE COUNT; MALE; PROSTATE BIOPSY; PROSTATE CANCER; UNITED KINGDOM;

EARLY DIAGNOSIS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 27844552392     PISSN: 00358843     EISSN: None     Source Type: Journal    
DOI: 10.1308/003588405X60696     Document Type: Article

References (4)

1. Furco A, Bani-Sadr F, Guymar S, Molina JM. Metastatic cancer of the prostate in a young HIV infected male patient. Presse Med 2003; 32: 930-1.
2. Schwartz JD, Prince D. Prostate cancer in HIV infection. AIDS 1996; 10: 797-8.
3. Dalgleish AG, O'Byrne KJ. Chronic immune activation and inflammation in the pathogenesis of AIDS and cancer. Adv Cancer Res 2002; 84: 231-76.
4. Rakowicz-Szulczynska EM, Jackson B, Snyder W. Prostate, breast and gynaecological cancer markers RAK with homology to HIV-1. Cancer Lett 1998; 124: 213-23.